- Vienna '18
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: M.Khan UK
Co Author(s): S. Ch'ng M. Muhtaseb
Back to previous
To evaluate the visual and refractive outcomes of cataract surgery with toric intraocular lens (IOL) implantation at a teaching hospital of the United Kingdom.
Singleton Hospital, Abertawe Bro Morgannwg University Local Health Board, Swansea, United Kingdom.
This study compared the outcome of 3 groups of patients: Group 1 included 25 eyes with cataract and more than 2.5 diopters (D) of corneal astigmatism receiving a toric monofocal IOL; Group 2 had 18 patients with cataract and more than 2.5 D of astigmatism but receiving a non-toric monofocal IOL; while Group 3 had 25 patients with cataract and less than 1.5 D of astigmatism and receiving a non-toric monofocal IOL. Data collected included uncorrected (UDVA) and corrected (CDVA) distance visual acuities, refraction and corneal keratometry. Postoperative examinations were scheduled at 1 and 6 weeks.
Postoperatively the mean UDVA was LogMAR 0.27 ±0.20 in Group 1, 0.54 ±0.22 in Group 2 and 0.16 ±0.20 in Group 3. The mean CDVA was LogMAR 0.08 ±0.13 in Group 1, 0.23 ±0.16 in Group 2 and 0.04 ±0.13 in Group 3. The mean preoperative keratometric cylinder was 3.78 ḟ1.0 D in Group 1, 3.41 ±1.47 D in Group 2 and 0.97 ±0.43D in Group 3; the mean postoperative subjective cylinder was 1.2 ±0.68 D in Group 1, 3.23 ±1.41 D in Group 2 and 0.95 ±0.58 D in Group 3. The difference was statistically significant for the postoperative refractive cylinder values when comparing Group 1 to Group 2 (P= <0.0001) but the difference was insignificant between Group 1 and Group 3 (P=0.23).
Toric IOL implantation is an effective option to manage corneal astigmatism at the time of cataract surgery and to optimise visual outcomes for astigmatic patients when comparing to outcomes for their non-astigmatic counterparts.
... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented